NAMPT

Choose Selective NAMPT Inhibitors

NAMPT Products

  • All (8)
  • NAMPT Inhibitors (6)
  • NAMPT Activators (2)
  • New NAMPT Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2799 Daporinad (FK866, APO866) Daporinad (FK866, APO866) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with IC50 of 0.09 nM in a cell-free assay. Daporinad (FK866, APO866) triggers autophagy. Phase 1/2.
Cancer Cell, 2021, S1535-6108(21)00338-X
Cell Metab, 2021, 33(1):110-127.e5
Free Radic Biol Med, 2021, 162:514-522
S6629 GNE-617 GNE-617 is a highly potent inhibitor of NAMPT activity with an IC50 of 5 nM.
S7316 STF-118804 STF-118804 is a highly specific NAMPT inhibitor.
Cell Rep, 2021, 36(6):109516
Cell Metab, 2020, 31(3):564-579
Neurochem Res, 2016, 41(9):2367-79
S8117 GMX1778 (CHS828) GMX1778 (CHS828) is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and Kd of < 25 nM and 120 nM, respectively. GMX1778 induces programmed cell death with apoptotic features. Phase 1.
Cancer Res, 2020, 80(4):890-900
Acta Physiol (Oxf), 2020, 10.1111/apha.13439
Signal Transduct Target Ther, 2017, 2:17017
S8444 KPT 9274 ( ATG-019) KPT 9274 ( ATG-019) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.
NAT CANCER, 2021, 2, 83–97
S9706New OT-82 OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03   nM in non-HP cancer cells and 2.89   nM in HP cancer cells, respectively.
S7968 P7C3 P7C3 is a potent proneurogenic and neuroprotective chemical that targets NAMPT enzyme.
S8980 SBI-797812 SBI-797812 is a NAMPT activator which is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 turns NAMPT into a "super catalyst" that more efficiently generates NMN.
S2799 Daporinad (FK866, APO866) Daporinad (FK866, APO866) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with IC50 of 0.09 nM in a cell-free assay. Daporinad (FK866, APO866) triggers autophagy. Phase 1/2.
Cancer Cell, 2021, S1535-6108(21)00338-X
Cell Metab, 2021, 33(1):110-127.e5
Free Radic Biol Med, 2021, 162:514-522
S6629 GNE-617 GNE-617 is a highly potent inhibitor of NAMPT activity with an IC50 of 5 nM.
S7316 STF-118804 STF-118804 is a highly specific NAMPT inhibitor.
Cell Rep, 2021, 36(6):109516
Cell Metab, 2020, 31(3):564-579
Neurochem Res, 2016, 41(9):2367-79
S8117 GMX1778 (CHS828) GMX1778 (CHS828) is a potent and specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with IC50 and Kd of < 25 nM and 120 nM, respectively. GMX1778 induces programmed cell death with apoptotic features. Phase 1.
Cancer Res, 2020, 80(4):890-900
Acta Physiol (Oxf), 2020, 10.1111/apha.13439
Signal Transduct Target Ther, 2017, 2:17017
S8444 KPT 9274 ( ATG-019) KPT 9274 ( ATG-019) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.
NAT CANCER, 2021, 2, 83–97
S9706New OT-82 OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03   nM in non-HP cancer cells and 2.89   nM in HP cancer cells, respectively.
S7968 P7C3 P7C3 is a potent proneurogenic and neuroprotective chemical that targets NAMPT enzyme.
S8980 SBI-797812 SBI-797812 is a NAMPT activator which is structurally similar to active-site directed NAMPT inhibitors and blocks binding of these inhibitors to NAMPT. SBI-797812 turns NAMPT into a "super catalyst" that more efficiently generates NMN.
S9706New OT-82 OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03   nM in non-HP cancer cells and 2.89   nM in HP cancer cells, respectively.